IQVIA Holdings
Market Cap
US$41.3b
Last Updated
2021/04/19 23:11 UTC
Data Sources
Company Financials +
Executive Summary
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More Details
Rewards
Risk Analysis
Snowflake Analysis
Proven track record with reasonable growth potential.
Similar Companies
Share Price & News
How has IQVIA Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IQV is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: IQV's weekly volatility (3%) has been stable over the past year.
Market Performance
7 Day Return
3.8%
IQV
2.2%
US Life Sciences
1.3%
US Market
1 Year Return
69.6%
IQV
62.3%
US Life Sciences
53.8%
US Market
Return vs Industry: IQV exceeded the US Life Sciences industry which returned 62.3% over the past year.
Return vs Market: IQV exceeded the US Market which returned 53.8% over the past year.
Shareholder returns
| IQV | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.8% | 2.2% | 1.3% |
| 30 Day | 14.8% | 8.2% | 5.1% |
| 90 Day | 14.4% | 2.9% | 8.9% |
| 1 Year | 69.6%69.6% | 62.5%62.3% | 56.6%53.8% |
| 3 Year | 120.6%120.6% | 116.7%115.4% | 64.4%53.6% |
| 5 Year | 208.9%208.9% | 216.1%212.3% | 120.4%95.7% |
Long-Term Price Volatility Vs. Market
How volatile is IQVIA Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
We Think Some Shareholders May Hesitate To Increase IQVIA Holdings Inc.'s (NYSE:IQV) CEO Compensation3 weeks ago | Simply Wall St
Is IQVIA Holdings Inc.'s (NYSE:IQV) ROE Of 4.9% Concerning?1 month ago | Simply Wall St
Is Now An Opportune Moment To Examine IQVIA Holdings Inc. (NYSE:IQV)?Valuation
Is IQVIA Holdings undervalued compared to its fair value and its price relative to the market?
148.25x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: IQV ($215.56) is trading above our estimate of fair value ($206.07)
Significantly Below Fair Value: IQV is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: IQV is poor value based on its PE Ratio (147.8x) compared to the US Life Sciences industry average (46.6x).
PE vs Market: IQV is poor value based on its PE Ratio (147.8x) compared to the US market (22.4x).
Price to Earnings Growth Ratio
PEG Ratio: IQV is poor value based on its PEG Ratio (5.2x)
Price to Book Ratio
PB vs Industry: IQV is good value based on its PB Ratio (6.9x) compared to the US Life Sciences industry average (7.9x).
Future Growth
How is IQVIA Holdings forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
28.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IQV's forecast earnings growth (28.4% per year) is above the savings rate (2%).
Earnings vs Market: IQV's earnings (28.4% per year) are forecast to grow faster than the US market (17.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: IQV's revenue (8.3% per year) is forecast to grow slower than the US market (9.3% per year).
High Growth Revenue: IQV's revenue (8.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IQV's Return on Equity is forecast to be high in 3 years time (23.7%)
Past Performance
How has IQVIA Holdings performed over the past 5 years?
-7.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IQV has high quality earnings.
Growing Profit Margin: IQV's current net profit margins (2.5%) are higher than last year (1.7%).
Past Earnings Growth Analysis
Earnings Trend: IQV's earnings have declined by 7.5% per year over the past 5 years.
Accelerating Growth: IQV's earnings growth over the past year (45.9%) exceeds its 5-year average (-7.5% per year).
Earnings vs Industry: IQV earnings growth over the past year (45.9%) exceeded the Life Sciences industry 7.4%.
Return on Equity
High ROE: IQV's Return on Equity (4.9%) is considered low.
Financial Health
How is IQVIA Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: IQV's short term assets ($5.1B) exceed its short term liabilities ($4.6B).
Long Term Liabilities: IQV's short term assets ($5.1B) do not cover its long term liabilities ($13.7B).
Debt to Equity History and Analysis
Debt Level: IQV's debt to equity ratio (200.5%) is considered high.
Reducing Debt: IQV had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: IQV's debt is not well covered by operating cash flow (15.6%).
Interest Coverage: IQV's interest payments on its debt are not well covered by EBIT (2x coverage).
Balance Sheet
Dividend
What is IQVIA Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IQV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IQV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IQV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IQV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: IQV is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IQV's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.5yrs
Average management tenure
CEO
Ari Bousbib (59 yo)
4.5yrs
Tenure
US$25,575,986
Compensation
Mr. Ari Bousbib serves as Chairman and Chief Executive Officer at IQVIA Holdings Inc. since October 2016 and also serves as its President. He has been the Chairman, Chief Executive Officer and President of...
CEO Compensation Analysis
Compensation vs Market: Ari's total compensation ($USD25.58M) is above average for companies of similar size in the US market ($USD11.16M).
Compensation vs Earnings: Ari's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: IQV's management team is considered experienced (4.5 years average tenure).
Board Members
Experienced Board: IQV's board of directors are considered experienced (4.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
IQVIA Holdings Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: IQVIA Holdings Inc.
- Ticker: IQV
- Exchange: NYSE
- Founded: 1982
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$41.337b
- Shares outstanding: 191.77m
- Website: https://www.iqvia.com
Number of Employees
Location
- IQVIA Holdings Inc.
- 83 Wooster Heights Road
- Danbury
- Connecticut
- 6810
- United States
Listings
Biography
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates throug...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/19 23:11 |
| End of Day Share Price | 2021/04/19 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.